Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study

BACKGROUND: Chronic liver disease (CLD) is often complicated by severe thrombocytopenia (platelet count < 50,000/µL). Platelet transfusion has been a gold standard for increasing the platelet count to prevent hemorrhagic events in such patients. Lusutrombopag, a thrombopoietin receptor agonist, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomoto, Hiroaki, Morimoto, Naoki, Miura, Kouichi, Watanabe, Shunji, Takaoka, Yoshinari, Maeda, Hiroshi, Sasaki, Takahiro, Koyashiki, Yohei, Kurata, Hidekazu, Numao, Norikatsu, Isoda, Norio, Yamamoto, Hironori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737263/
https://www.ncbi.nlm.nih.gov/pubmed/33317473
http://dx.doi.org/10.1186/s12876-020-01573-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737263/
https://www.ncbi.nlm.nih.gov/pubmed/33317473
http://dx.doi.org/10.1186/s12876-020-01573-9

Ejemplares similares